 |
|
Effect of Rimonabant on Weight and Cardiometabolic Risk Factors
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Pi-Sunyer and colleagues1 reported the results of the RIO-North America trial on the efficacy of rimonabant for weight loss. In this study, patients who received 20 mg of rimonabant daily had a 2.7-fold higher rate of psychiatric disorders (leading to early withdrawal or removal from the study) compared with those receiving placebo. Psychiatric adverse events have accounted for about half of all early terminations attributed to adverse events with the 20 mg of rimonabant dose in all RIO trials published to date. In the RIO-Europe trial,2 of the 14.5% of patients who withdrew early during treatment with 20 mg of rimonabant daily, 7.0% were attributed to psychiatric adverse events. In the RIO-Lipids trial,3 psychiatric adverse events accounted for 7.5% of patients withdrawing early during treatment with 20 mg of rimonabant daily, whereas only 2.3% withdrew in the placebo group for the same reasons (a 3.3-fold increase . . . [Full Text of this Article]
Kishore M. Gadde, MD
gadde001@mc.duke.edu
Obesity Clinical Trials Programme
Duke University Medical Centre
Durham, NC
RELATED ARTICLES
Effect of Rimonabant on Weight and Cardiometabolic Risk Factors—Reply
F. Xavier Pi-Sunyer
JAMA. 2006;296(6):650-651.
EXTRACT
| FULL TEXT
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial
F. Xavier Pi-Sunyer, Louis J. Aronne, Hassan M. Heshmati, Jeanne Devin, Julio Rosenstock, and for the RIO-North America Study Group
JAMA. 2006;295(7):761-775.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT
|
